Cargando…

Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes

BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn f...

Descripción completa

Detalles Bibliográficos
Autores principales: Alatab, Sudabeh, Fakhrzadeh, Hossein, Sharifi, Farshad, Mostashfi, Ali, Mirarefin, Mojde, Badamchizadeh, Zohreh, Tagalizadehkhoob, Yaser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933380/
https://www.ncbi.nlm.nih.gov/pubmed/24476202
http://dx.doi.org/10.1186/2251-6581-13-24
_version_ 1782304924161277952
author Alatab, Sudabeh
Fakhrzadeh, Hossein
Sharifi, Farshad
Mostashfi, Ali
Mirarefin, Mojde
Badamchizadeh, Zohreh
Tagalizadehkhoob, Yaser
author_facet Alatab, Sudabeh
Fakhrzadeh, Hossein
Sharifi, Farshad
Mostashfi, Ali
Mirarefin, Mojde
Badamchizadeh, Zohreh
Tagalizadehkhoob, Yaser
author_sort Alatab, Sudabeh
collection PubMed
description BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive, and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured. RESULTS: Diabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19, p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93, 95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI. CONCLUSIONS: Since FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients, influence of HTN on these markers might be different.
format Online
Article
Text
id pubmed-3933380
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39333802014-02-25 Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes Alatab, Sudabeh Fakhrzadeh, Hossein Sharifi, Farshad Mostashfi, Ali Mirarefin, Mojde Badamchizadeh, Zohreh Tagalizadehkhoob, Yaser J Diabetes Metab Disord Research Article BACKGROUND: Presence of Diabetes Mellitus increases the risk of subclinical atherosclerosis. In this study was aimed to determine the influence of hypertension (HTN) on surrogate markers of atherosclerosis in a population of patients with early type 2 diabetes. METHODS: 125 diabetic subjects drawn from Dr. Shariati outpatient’s clinic list and 153 non- diabetic subjects who were the relatives in law of diabetic participants were recruited. Participants with type 2 diabetes were free of clinical evidence of cardiovascular disease and renal involvement. Two groups of diabetic and control were further divided into two subgroups of hypertensive (known case of HTN or blood pressure ≥140/90 mmHg) and normotensive, and anthropometric characteristics, metabolic biomarkers as well as markers of subclinical atherosclerosis including Carotid intima media thickness (CIMT), flow mediated dilation (FMD) and Ankle Brachial Index (ABI) were measured. RESULTS: Diabetic group with a mean age of 49.9 ± 7.5 years had significantly higher CIMT (0.64 ± 0.14 vs 0.76 ± 0.19, p = 0.001) and lower FMD (16.5 ± 8.1 vs 13.3 ± 7.1, p = 0.003) and ABI (1.2 ± 0.1 vs 1.1 ± 0.1, p = 0.01) than control with mean age of 52.9 ± 10.1 years. 34% of control and 59.2% of diabetic were hypertensive. Fasting blood sugar, insulin levels and calculated insulin resistance index of HOMA IR. of hypertensive subjects were higher than normotensive subjects in both groups of diabetic and non-diabetic. Similar pattern was presented for measured inflammatory mediators of hs-CRP and IL-6. Among subclinical atherosclerosis markers, only CIMT was significantly different between hypertensive and normotensive subjects in both groups. In adjusted linear regression analysis, a constant significant association existed between age and CIMT, ABI and FMD in non-diabetic, while in diabetic, age only correlated with CIMT and not the other two markers. In multiple regression model, HTN was recognized as a risk factor for increasing CIMT (OR = 2.93, 95% CI = 1.03-8.33, p = 0.04) but not attenuating FMD or ABI. CONCLUSIONS: Since FMD and CIMT may measure a different stage of subclinical atherosclerosis in diabetic patients, influence of HTN on these markers might be different. BioMed Central 2014-01-29 /pmc/articles/PMC3933380/ /pubmed/24476202 http://dx.doi.org/10.1186/2251-6581-13-24 Text en Copyright © 2014 Alatab et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Alatab, Sudabeh
Fakhrzadeh, Hossein
Sharifi, Farshad
Mostashfi, Ali
Mirarefin, Mojde
Badamchizadeh, Zohreh
Tagalizadehkhoob, Yaser
Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title_full Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title_fullStr Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title_full_unstemmed Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title_short Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
title_sort impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933380/
https://www.ncbi.nlm.nih.gov/pubmed/24476202
http://dx.doi.org/10.1186/2251-6581-13-24
work_keys_str_mv AT alatabsudabeh impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT fakhrzadehhossein impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT sharififarshad impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT mostashfiali impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT mirarefinmojde impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT badamchizadehzohreh impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes
AT tagalizadehkhoobyaser impactofhypertensiononvariousmarkersofsubclinicalatherosclerosisinearlytype2diabetes